STL Volume 17 Number 4

Update on drugs, approval dates, and comments. Ivermectin 0.5% lotion (Sklice™), Ipilimumab (Yervoy™), Vemurafenib (Zelboraf®), are covered, as well as the Cellulite removal laser device Cellulaze™ Cellulite Laser Workstation.

Imiquimod 3.75% cream has recently been approved by both the FDA and Health Canada for the treatment of external genital warts. This article is an overview of EGW, phase 3 clinical trials leading to the approval of imiquimod 3.75% cream, and comparison with imiquimod 5% cream.

Biologic compounds are being used more frequently to treat a multitude of systemic inflammatory conditions. This article discusses the increased risk of opportunistic infections of tuberculosis, herpes zoster, Legionella pneumophila, and Listeria monocytogenes.